Medvi: a two-person telehealth company run on AI tools, projecting $1.8B in revenue
Medvi started with $20,000 and two people, posted $401M in its first full year and projects $1.8B for 2026. Reports also record its chatbot inventing prices.
Medvi started with $20,000 and now has two people. It posted $401 million in sales in its first full year and projects $1.8 billion in revenue for 2026, with a 16.2% net margin (Hims & Hers: 5.5%). A dozen or so AI tools handle code, copy, ad creative and customer service, while doctors and pharmacy fulfillment are outsourced.
At a glance
| Item | Detail |
|---|---|
| Company | Medvi (Matthew Gallagher) |
| Industry | Healthcare |
| Use cases | Process optimization, customer interaction, business intelligence |
| Functions involved | Marketing, customer experience, business intelligence |
| Reported results | $20,000 starting capital → $401M first-full-year sales; 250,000 customers; 16.2% net margin; $1.8B revenue projected for 2026 |
| Moments rating | S (quick win) |
| AI scenario score | 92 |
Case details
Background
Matthew Gallagher founded Medvi, a telehealth company selling GLP-1 weight-loss drugs, from his Los Angeles home in September 2024. He started with $20,000, no employees and about a dozen AI tools. According to PYMNTS on April 3, 2026, citing a New York Times report from April 2, the company still has just two people; the only employee is his brother Elliot.
What they did
- Code and copy: ChatGPT, Claude and Grok. Ad creative: Midjourney and Runway. Voice customer communication: ElevenLabs.
- Custom AI agents connect the systems and monitor performance in real time.
- Outsourced the licensed work. Physicians, prescription handling, pharmacy delivery, logistics and compliance go to CareValidate and OpenLoop Health. Medvi keeps only the brand, website, paid acquisition, checkout and customer service.
Results and data
Medvi reported $401 million in sales in its first full year, 250,000 customers and a 16.2% net margin, and projects $1.8 billion in revenue for 2026. For comparison, Hims & Hers had $2.4 billion in revenue the prior year, 2,442 employees and a 5.5% net margin.
The reporting also records problems. The customer service bot initially made up drug prices (Gallagher honored the wrong prices) and invented product lines that did not exist; people had to correct both. The report mentions no regulatory penalties.
What to take from it
- Outsourcing the licensed, asset-heavy parts and keeping only acquisition and conversion is what lets two people carry this much revenue.
- AI mainly replaces content production and customer service staff, not the medical service itself.
- Customer-facing bots need hard limits on prices and the product catalog; otherwise errors turn straight into costs.
Limits
Online consultations and prescription drug sales require strict licensing in many markets, including China, so the model cannot simply be copied. The high margin depends on demand for GLP-1 drugs and on partners’ fulfillment capacity. The headline raises regulatory risk, but the source gives no specific incident, so follow later developments yourself.
Source
Original source: Medvi case material (PYMNTS)
This entry is industry research: a publicly documented, third-party AI case. It is not a Moments client case. For work Moments delivered itself, see client cases.
Related
- Nat Eliason / Felix: an OpenClaw agent running its own small business — Nat Eliason gave his OpenClaw agent Felix $1,000 to run a website, info product and X account; it reported $14,718 in revenue (not profit) in about 3 weeks.
- AI agent — An AI agent is a program that plans its own steps, calls tools and adjusts based on results to reach a goal, rather than just generating a block of text.
- AI search optimization for healthcare brands — For healthcare brands, AI search optimization means AI assistants describe your organization, services and credentials accurately, within advertising rules.